Nivetha Ganesan

1.2k total citations
23 papers, 370 citations indexed

About

Nivetha Ganesan is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Nivetha Ganesan has authored 23 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 8 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Nivetha Ganesan's work include Lymphoma Diagnosis and Treatment (9 papers), T-cell and Retrovirus Studies (4 papers) and Cutaneous lymphoproliferative disorders research (4 papers). Nivetha Ganesan is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), T-cell and Retrovirus Studies (4 papers) and Cutaneous lymphoproliferative disorders research (4 papers). Nivetha Ganesan collaborates with scholars based in United States, Israel and Australia. Nivetha Ganesan's co-authors include Ahmet Doǧan, Natasha Galasso, Steven M. Horwitz, Paola Ghione, Ai Ni, Peter G. Cordeiro, Qunying Hu, Anjana Bhardwaj, Isabelle Bedrosian and Kazunoshin Tachibana and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Nivetha Ganesan

20 papers receiving 359 citations

Peers

Countries citing papers authored by Nivetha Ganesan

Since Specialization

Citations

This map shows the geographic impact of Nivetha Ganesan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nivetha Ganesan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nivetha Ganesan more than expected).

Fields of papers citing papers by Nivetha Ganesan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nivetha Ganesan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nivetha Ganesan. The network helps show where Nivetha Ganesan may publish in the future.

Co-authorship network of co-authors of Nivetha Ganesan

This figure shows the co-authorship network connecting the top 25 collaborators of Nivetha Ganesan. A scholar is included among the top collaborators of Nivetha Ganesan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nivetha Ganesan. Nivetha Ganesan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dermatologic Adverse Events in Patients Receiving Duvelisib Single-Agent and Combination Therapies 2025 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Nivetha Ganesan, Stephen W. Dusza, Steven M. Horwitz, Alison J. Moskowitz, Shamir Geller	1
2	Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience 2024 ·Blood ·Efrat Luttwak, (unknown), Esther Drill, Nivetha Ganesan, (unknown), Ronit Gurion, Shlomzion Aumann, (unknown), (unknown), (unknown), Robert Stuver, Paul A. Hamlin, Ariela Noy, Alex F. Herrera, Alison J. Moskowitz	0
3	Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies 2023 ·Blood ·Robert Stuver, Esther Drill, Nivetha Ganesan, (unknown), (unknown), (unknown), (unknown), (unknown), Natasha Galasso, Alex F. Herrera, Matthew Mei, Reid W. Merryman, Ivana N. Micallef, Harsh Shah, Alison J. Moskowitz	1
4	Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified: Characterization of a Large Cohort with Long-Term Outcomes Shows Disparate Outcomes By Body Region Involvement 2022 ·Blood ·Robert Stuver, Paola Ghione, Nivetha Ganesan, Sarah Noor, Brandon S. Imber, Melissa Pulitzer, Sarah McCue Horwitz	1
5	Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant. 2022 ·Journal of Clinical Oncology ·Robert Stuver, (unknown), Nivetha Ganesan, Steven M. Horwitz, Alison J. Moskowitz	0
6	Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade 2021 ·Blood ·Beatriz Wills, Laure Michaud, Heiko Schöder, Nivetha Ganesan, Craig H. Moskowitz, David J. Straus, Lorenzo Falchi, Matthew J. Matasar, Andrew D. Zelenetz, Erel Joffe, Gottfried von Keudell, Connie Lee Batlevi, Audrey Hamilton, Philip Caron, Ariela Noy, Gilles Salles, Alison J. Moskowitz	0
7	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience 2021 ·Leukemia & lymphoma ·Zachary D. Epstein‐Peterson, Nivetha Ganesan, Juliet N. Barker, Pamela Drullinsky, Paola Ghione, Ann A. Jakubowski, Anita Kumar, Alison J. Moskowitz, Ariela Noy, Miguel‐Angel Perales, Doris M. Ponce, Heiko Schöder, James W. Young, Sergio Giralt, Steven M. Horwitz, Craig S. Sauter, Parastoo B. Dahi	3
8	TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy 2021 ·Blood ·W. Thomas Johnson, Nivetha Ganesan, Zachary D. Epstein‐Peterson, (unknown), Natasha Galasso, Craig S. Sauter, (unknown), Niloufer Khan, Alison J. Moskowitz, Ahmet Doǧan, Steven M. Horwitz	2
9	A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS 2021 ·Hematological Oncology ·Niloufer Khan, Sarah Noor, Shamir Geller, Michael S. Khodadoust, Meenal Kheterpal, Helen Hancock, Theresa Davey, S. Y. Ryu, (unknown), (unknown), Nivetha Ganesan, (unknown), (unknown), Natasha Galasso, (unknown), Patricia L. Myskowski, Y. H. Kim, Sarah McCue Horwitz, Alison J. Moskowitz	3
10	Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants 2020 ·Journal of Plastic Reconstructive & Aesthetic Surgery ·Peter G. Cordeiro, Paola Ghione, Ai Ni, Qunying Hu, Nivetha Ganesan, Natasha Galasso, Ahmet Doǧan, Steven M. Horwitz	125
11	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma 2020 ·Blood Advances ·Paola Ghione, (unknown), Neha Mehta–Shah, Venkatraman Seshan, Neval Özkaya, Shakthi Bhaskar, (unknown), Michael A. Spinner, Matthew A. Lunning, Giorgio Inghirami, Alison J. Moskowitz, Natasha Galasso, Nivetha Ganesan, Carrie van der Weyden, Jia Ruan, H. Miles Prince, Judith Trotman, Ranjana H. Advani, Ahmet Doǧan, Steven M. Horwitz	56
12	RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA‐ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS 2019 ·Hematological Oncology ·Paola Ghione, (unknown), Ai Ni, (unknown), Nivetha Ganesan, Natasha Galasso, Ahmet Doǧan, Steven M. Horwitz	2
13	Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3,546 women prospectively followed after receiving textured breast implants. 2019 ·Journal of Clinical Oncology ·Paola Ghione, Peter G. Cordeiro, Ai Ni, Qunying Hu, Nivetha Ganesan, Natasha Galasso, Ahmet Doǧan, Steven M. Horwitz	12
14	Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer 2017 ·Oncotarget ·Anjana Bhardwaj, Harpreet Singh, Kimal Rajapakshe, Kazunoshin Tachibana, Nivetha Ganesan, Yinghong Pan, Preethi H. Gunaratne, Cristian Coarfa, Isabelle Bedrosian	43
15	In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma 2017 ·Blood ·Alison J. Moskowitz, Raphael Koch, Neha Mehta–Shah, Patricia L. Myskowski, Meenal Kheterpal, Ahmet Doǧan, Theresa Davey, Natasha Galasso, (unknown), Monica Shah, Nivetha Ganesan, (unknown), Youn H. Kim, Michael S. Khodadoust, (unknown), Julia Dai, Eric D. Jacobsen, David M. Weinstock, Steven M. Horwitz	11
16	Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling 2015 ·PLoS ONE ·Anjana Bhardwaj, Nivetha Ganesan, Kazunoshin Tachibana, Kimal Rajapakshe, Constance T. Albarracin, Preethi H. Gunaratne, Cristian Coarfa, Isabelle Bedrosian	29
17	Abstract 3982: Targeting of miRNA networks for prevention of basal-like breast cancers 2015 ·Cancer Research ·Anjana Bhardwaj, Kazunoshin Tachibana, Nivetha Ganesan, Yinghong Pan, (unknown), Cristian Coarfa, Preethi H. Gunaratne, Isabelle Bedrosian	1
18	Suppression of Akt-mTOR Pathway-A Novel Component of Oncogene Induced DNA Damage Response Barrier in Breast Tumorigenesis 2014 ·PLoS ONE ·Anjana Bhardwaj, Daniel Rosen, Mei Liu, (unknown), Qiang Hao, Nivetha Ganesan, Carol J. Etzel, (unknown), Constance T. Albarracin, Isabelle Bedrosian	10
19	Abstract A115: Annexin A1: A novel gene target of miRNA-21 2013 ·Molecular Cancer Research ·Anjana Bhardwaj, Nivetha Ganesan, Constance T. Albarracin, Isabelle Bedrosian	1
20	Lubiprostone Activates Cl− Secretion via cAMP Signaling and Increases Membrane CFTR in the Human Colon Carcinoma Cell Line, T84 2010 ·Digestive Diseases and Sciences ·Mei Ao, (unknown), Chaiwat Boonkaewwan, Nivetha Ganesan, (unknown), Richard V. Benya, Mrinalini C. Rao	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact